Rocket Pharmaceuticals shares are poised to nearly quadruple as it rolls out its lineup of late-stage targeted gene therapies, according to Cantor Fitzgerald.
RCKT YTD mountain RCKT YTD chart Analyst Josh Schimmer called the stock one of his "top picks" as its products address unmet medical needs.
It also benefits from a "thoughtful management team with a knack for identifying compelling gene therapy programs," he said.
Schimmer is extremely bullish on Rocket's portfolio of advanced gene therapy products.
"RCKT should be stacking larger and larger gene therapy programs," the analyst wrote.
Persons:
Cantor Fitzgerald, Josh Schimmer, Schimmer, — CNBC's Michael Bloom
Organizations:
Rocket Pharmaceuticals